Cancer Therapy Advisor has updated its treatment regimen chart for the treatment of melanoma to reflect the most recent changes put forth by Version 3.2016 of the National Comprehensive Cancer Network (NCCN) Guidelines for Bone Cancer.
Key updates from Version 2.2016 and Version 1.2016 for the systemic treatment of metastatic or unresectable melanoma include:
- For both first- and second-line or subsequent targeted therapy, the recommended combination regimens are listed as “preferred” over single-agent therapy options.
- Vemurafenib plus cobimetinib was added as a preferred first-line treatment option with a Category 1 recommendation.
- Vemurafenib plus cobimetinib was added as a second-line or subsequent treatment option.
Footnote i was added: Vemurafenib/cobimetinib combination therapy was associated with better PFS and a better response rate than vemurafenib monotherapy in previously untreated patients with unresectable stage IIIC or stage IV disease. The combination’s effect on OS compared to single-agent vemurafenib is unknown.
Continue Reading
Reference
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma. V 3.2016. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Updates July 7, 2016. Accessed September 6, 2016.
